Methods for detecting human methylenetetrahydrofolate reductase allelic variants
First Claim
Patent Images
1. A method for treating an individual having an MTHFR allele variant, said method comprising:
- (a) analyzing a nucleic acid sample obtained from said individual to determine whether said sample comprises at least one MTHFR allele variant, said variant leading to a decrease in MTHFR activity; and
(b) treating said individual having said MTHFR allele variant.
1 Assignment
0 Petitions
Accused Products
Abstract
Provided herein is a heretofore unknown isolated nucleic acid molecule which encodes human methylenetetrahydrofolate reducatase, along with an amino acid sequence of methylenetetrahydrofolate reductase, and a cDNA probe for human methylenetetrahydrofolate reductase. Also provided are a molecule description of mutations in humans resulting in a phenotype having reduced levels of methylenetetrahydrofolate reductase, and methods of diagnosing methylenetetrahydrofolate reductase deficiency in a human.
-
Citations
52 Claims
-
1. A method for treating an individual having an MTHFR allele variant, said method comprising:
-
(a) analyzing a nucleic acid sample obtained from said individual to determine whether said sample comprises at least one MTHFR allele variant, said variant leading to a decrease in MTHFR activity; and
(b) treating said individual having said MTHFR allele variant. - View Dependent Claims (2, 3, 4, 5, 6, 7, 34, 35, 36, 37)
-
-
8. A method for treating an individual having an MTHFR allele variant, said method comprising:
-
(a) analyzing a nucleic acid sample obtained from said individual to determine whether said sample comprises the MTHFR allele variant 1317T/C, said variant leading to a decrease in MTHFR activity; and
(b) treating said individual having said MTHFR allele variant. - View Dependent Claims (9, 10, 11, 12, 13, 52)
-
-
14. A method for treating an individual having an MTHFR allele variant, said method comprising:
-
(a) analyzing a nucleic acid sample obtained from said individual to determine whether said sample comprises at least one MTHFR allele variant, said variant leading to a decrease in MTHFR activity; and
(b) treating said individual having said MTHFR allele variant with a treatment that affects folate acid metabolism and leads to an increased level of folate or to a decreased level of homocysteine, wherein said treatment is for a disorder selected from the group consisting of cardiovascular disorders, coronary and arterial disorders, osteoporosis, and neurological disorders. - View Dependent Claims (15, 16, 17, 18, 19, 24)
-
-
20. A method for selecting a treatment affecting folic acid metabolism for an individual having an MTHFR allele variant, said method comprising:
-
(a) analyzing a nucleic acid sample obtained from said individual to determine whether said sample comprises at least one MTHFR allele variant, said variant leading to a decrease in MTHFR activity; and
(b) selecting a treatment that affects folate metabolism and leads to an increased level of folate or to a decreased level of homocysteine. - View Dependent Claims (21, 22, 23, 38, 39, 40, 41, 42, 43, 45, 46, 51)
-
-
25. A method for selecting a treatment affecting folate metabolism for an individual having an MTHFR allele variant, said method comprising:
-
(a) analyzing a nucleic acid sample obtained from said individual to determine whether said sample comprises the MTHFR allele variant 1317T/C, said variant leading to a decrease in MTHFR activity; and
(b) selecting a treatment that affects folate metabolism and leads to an increased level of folate or to a decreased level of homocysteine. - View Dependent Claims (26, 27, 28, 44)
-
-
29. A method for selecting a treatment affecting folate metabolism for an individual having an MTHFR allele variant, said method comprising:
-
(a) analyzing a nucleic acid sample obtained from said individual to determine whether said sample comprises at least one MTHFR allele variant, said variant leading to a decrease in MTHFR activity; and
(b) selecting a treatment that affects folate metabolism and leads to an increased level of folate or to a decreased level of homocysteine, wherein said treatment is for a disorder selected from the group consisting of cardiovascular disorders, coronary and arterial disorders, osteoporosis, and neurological disorders. - View Dependent Claims (30, 31, 32)
-
-
33. A method for selecting a treatment that has increased or decreased drug responsiveness in an individual having an MTHFR allele variant, said method comprising:
-
(a) analyzing a nucleic acid sample obtained from said individual to determine whether said sample comprises at least one MTHFR allele variant, said variant leading to a decrease in MTHFR activity, and said variant being correlated to increased or decreased drug responsiveness to an antiarthritic agent; and
(b) selecting a treatment known to have increased or decreased drug responsiveness in an individual having said MTHFR allele, wherein said treatment is selected from the group consisting of antiarthritic agents, and wherein said treatment affects folate metabolism and leads to an increased level of folate or to a decreased level of homocysteine. - View Dependent Claims (47, 48, 49, 50)
-
Specification